首页BVNRY • OTCMKTS
add
巴伐利亞北歐
市场资讯
财务信息
损益表
收入
净收入
| (DKK) | 2024年6月info | 年同比变化 |
|---|---|---|
收入 | 14.27亿 | -28.14% |
经营支出 | 4.54亿 | -39.99% |
净收入 | 2.61亿 | -51.47% |
净利润率 | 18.29 | -32.48% |
每股收益 | 3.30 | -53.52% |
息税折旧摊销前利润 | 4.20亿 | -39.17% |
有效税率 | 1.83% | — |
资产负债表
总资产
负债总额
| (DKK) | 2024年6月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 22.37亿 | 61.35% |
总资产 | 142.74亿 | -4.79% |
负债总额 | 38.38亿 | -27.69% |
权益总额 | 104.37亿 | — |
发行在外的股份 | 7912.97万 | — |
市净率 | 0.08 | — |
资产回报率 | 4.77% | — |
资本回报率 | 6.37% | — |
现金流
现金净变动
| (DKK) | 2024年6月info | 年同比变化 |
|---|---|---|
净收入 | 2.61亿 | -51.47% |
来自运营的现金 | 6.31亿 | 42.57% |
投资现金 | -6.51亿 | 36.99% |
融资现金 | -2649.40万 | -117.67% |
现金净变动 | -4441.20万 | 89.90% |
自由现金流 | -2.43亿 | -159.79% |
简介
Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany and San Diego, California, as well as offices in Zug, Switzerland, and Morrisville, North Carolina. The company uses viral vectors and virus-like particles in its research and development. Wikipedia
CEO
成立时间
1992年7月1日
员工数量
1,381
